Tumor Immunity in Perforin-Deficient Mice: A Role for CD95 (Fas/APO-1)1
Tumor Immunity in Perforin-Deficient Mice: A Role for CD95 (Fas/APO-1)1
复制标题
穿孔素缺陷小鼠的肿瘤免疫:CD95 (Fas/APO-1)1 的作用
作者:
D. Rosen;Jie;S. Keidar;I. Markon;R. Orda;G. Berke
CTL and NK cells use two distinct cytocidal pathways: 1) perforin and granzyme based and 2) CD95L/CD95 mediated. The former requires perforin expression by the effectors (CTL or NK), whereas the latter requires CD95 (Fas/APO-1) expression by the target. We have investigated how these two factors contribute to tumor immune surveillance by studying the immunity of perforin-deficient mice against the progressor C57BL/6 Lewis lung carcinoma 3LL, which expresses no CD95 when cultured in vitro. Unexpectedly, the results indicated that the perforin-independent CD95L/CD95 pathway of CTL/NK plays a role in acting against D122 and Kb39.5 (39.5) high and low metastatic sublines, respectively, derived from the 3LL tumor. Although no membrane-bound CD95 was detected on cultured D122 and 39.5 cells, surface CD95 expression on both D122 and 39.5 was considerably up-regulated when the tumors were grown in vivo. A similarly enhanced expression of CD95 was observed with three additional tumors; LF−, BW, and P815, injected into syngeneic and allogeneic mice. The finding of up-regulated CD95 expression on tumor cells placed in vivo suggests that a CD95-based mechanism plays a role in tumor immunity at early stages of tumor growth. Consequently, the progressive down-regulation of CD95 expression during tumor progression may indeed be an escape mechanism as previously reported. Together, these results suggest a role for CD95-dependent, perforin-independent immunity against certain tumors.
影响因子:
20.3
作者:
Bradley, M;Zeytun, A;Nagarkatti, M
通讯作者:
Nagarkatti, M
DOI:
--
发表时间:
1994
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Walsh,CM;Glass,AA;Chiu,V;Clark,WR
通讯作者:
Clark,WR
DOI:
10.1073/pnas.91.23.10854
发表时间:
1994-11-08
影响因子:
11.1
作者:
WALSH, CM;MATLOUBIAN, M;CLARK, WR
通讯作者:
CLARK, WR